Reimbursement to a subject of ancillary costs under the program:
(1) does not constitute an inducement to participate in a cancer clinical trial;
(2) is not considered coercion or the exertion of undue influence to participate in a cancer clinical trial; and
(3) is meant to accomplish parity in access to cancer clinical trials and remove barriers to participation in cancer clinical trials for financially burdened subjects.